Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
altSonflex1-2-3 Low Dose
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**altSonflex1-2-3 Low Dose** is the Dose A formulation of GSK's investigational tetravalent GMMA-based Shigella vaccine candidate, now licensed to Bharat Biotech for continued development. It contains 3.75 µg of O-antigen from each of four targeted Shigella serotypes—*Shigella sonnei* and *Shigella flexneri* serotypes 1b, 2a, and 3a—and is intended to prevent shigellosis. The vaccine uses Generalized Modules for Membrane Antigens, which are bacterial outer-membrane-vesicle particles carrying serotype-specific lipopolysaccharide O-antigen; vaccination is designed to induce functional anti-O-antigen serum antibodies, including bactericidal antibodies, that protect against Shigella infection. The low-dose formulation was evaluated in the completed Phase I/II dose-finding study NCT05073003, including a three-dose regimen in infants. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech-for-continued-development/))
- Other names
- altSonflex1-2-3 Dose AaltSonflex-1-2-3 Dose AaltSonflex 1-2-3 Dose A
02
Targets
Shigella flexneri serotype 1b O-antigen lipopolysaccharideShigella flexneri 3a O-antigen lipopolysaccharideShigella sonnei O-specific polysaccharide
Beyond the preview
Go deeper on altSonflex1-2-3 Low Dose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on altSonflex1-2-3 Low Dose.